AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry

NetraMark: Clinical research even with small data sets

After SAP announced its AI collaboration with OpenAI and Amazon, its share price jumped significantly. Observers see the partnership as the next logical step. It is now clear that Europe aims to develop its own AI infrastructure. Amazon is building data centers in Brandenburg for this purpose through its AWS cloud service. In the future, the two companies also aim to advance the digitization of German companies and support them in developing AI applications based on their own data. This step makes perfect sense: SAP systems already store vast amounts of data, often with long historical records. So far, however, relatively few small and mid-sized companies have considered leveraging this treasure trove of data for their own benefit.

When one hears how professional thinkers such as philosopher Markus Gabriel assess the possibilities of AI, it quickly becomes clear that there is enormous potential here. The Canadian company NetraMark has been harnessing this potential for several years and applying the possibilities of AI in medical research. The Company's proprietary NetraAI platform is based on a novel "topology-based" algorithm that segments patient records into homogeneous subgroups. This enables NetraMark to work with even small data sets, differentiate diseases into precise subtypes, and classify patients based on drug sensitivity. This expertise helps to set up drug studies in such a way that maximizes the likelihood of success.

Collaborations on glioblastoma and pediatric heart disease

NetraAI enables researchers to plan drug studies in a more targeted manner, for example, by selecting appropriate inclusion criteria and biomarkers. Just a few days ago, NetraMark announced a collaboration with a leading US research center on glioblastoma, a particularly aggressive brain tumor. Through this partnership, the Canadians will gain access to extensive data, which NetraAI will analyze and derive explainable patient subgroups from it. According to NetraMark President Josh Spiegel, these subgroups will facilitate the discovery of new biomarkers. In the summer of 2025, NetraMark entered into a collaboration with Asklepion Pharmaceuticals. The biotech company is using NetraMark technology in a Phase III study for pediatric heart disease. This technology is particularly valuable for studies with a limited number of participants.

Also in the summer, NetraMark announced a collaboration with data analysis specialist Pentara. The goal: to detect anomalies in clinical trials using AI – undetected data integrity issues can distort efficacy signals and compromise the validity of study conclusions. The earlier researchers detect these anomalies, the better. After months without announcing any major collaborations, the three company announcements show that NetraMark's technology is compatible with many areas. The tech company was already working with the contract research organization Worldwide Clinical Trials – it seems that NetraMark is convincing more and more industry representatives.

Versatile connectivity – What is next for NetraMark shares?

Considering that the development of a new active ingredient typically takes many years – industry representatives cite 10–15 years – and costs hundreds of millions to several billion USD, it becomes clear how much leverage NetraMark offers to biotech companies. The stock has recently seen a jump, but over the past six months, it has only posted a return of around 20%. The market capitalization of just around EUR 80 million does not yet indicate any exaggeration. NetraMark is an AI stock with interesting prospects. If it succeeds in concluding its existing partnerships, the Company is likely to generate follow-up orders or even attract the attention of major pharmaceutical companies or contract research organizations. AI is a technology poised to transform many sectors of the economy, and its advantages in biotechnology are obvious. NetraMark has already successfully occupied this niche. Given these fundamentals, the stock has significant potential, and the market does not yet appear to have fully priced it in.